Edaravone Mitsubishi-Tokyo.

R, Tabrizchi

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2001

Data sources: Europe PubMed Central

Edaravone Mitsubishi-Tokyo.

descriptionPublicationkeyboard_double_arrow_right Article 17 May 2001 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 1 (issn: 1472-4472,

Copyright policy )

Authors: R, Tabrizchi;

pmid: 11249718

Edaravone Mitsubishi-Tokyo.

- Summary
- Subjects
- Metrics

Abstract

Mitsubishi-Tokyo (formerly Mitsubishi Chemical) is developing edaravone (norphenazone), a free radical scavenger, for the potential treatment of cardiovascular disease, cerebrovascular ischemia and cerebral edema. By February 2000, edaravone had been filed in Japan for the treatment of acute brain infarction, and was in phase III trials for subarachnoid hemorrhage [365460]. The compound blocks the action of the lipoperoxide, 15-HPETE, which normally increases with age and may be associated with neurodegeneration.

Related Organizations

Memorial University of Newfoundland
Canada
Health Sciences Centre
Canada

Keywords

Clinical Trials as Topic, Cardiovascular Diseases, Contraindications, Edaravone, Humans, Drugs, Investigational, Free Radical Scavengers, Antipyrine

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	28
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%